Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price
DNAStock
$10.27−32.08%52W
Market Cap$691.58M
P/E—
PEG Ratio—
Div yield—
Beta1.70
DNA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)23.13%
Price vs S&P 500 (4W)30.02%
VGM Score49.53
DNA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.70 | -$0.73 | -4.66%(-$0.03) | |
| Q1 2026 | -$1.34 | -$1.39 | -3.73%(-$0.05) | |
| Q4 2025 | -$1.11 | -$0.77 | +30.50%(+$0.34) | |
| Q3 2025 | -$1.24 | -$1.45 | -16.94%(-$0.21) | |
| Q2 2025 | -$1.57 | -$1.10 | +29.79%(+$0.47) |
DNA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
2.20
2.20
2.20
2.10
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
DNAGinkgo Bioworks Holdings, Inc. | C | D | B | 6.2x | -51.5% | 77.7% | — | $10.27 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks provides a cell programming platform offering biological R&D services and end-to-end solutions across pharmaceuticals, agriculture, food, and industrial markets. The company operates two segments: Cell Engineering, which generates the majority of revenue through customer biological research and development, and Biosecurity, which provides biological threat identification, monitoring, and mitigation services for government and commercial customers.